Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

Background Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with high morbidity and mortality. Empagliflozin, an SGLT2 (sodium–glucose cotransporter 2) inhibitor, reduces adverse events in patients with HFpEF regardless of glycemic control. However, the precise cardi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinyu Hu, Dan Li, Weijie Chen, Hongyu Kuang, Dan Yang, Zhiyan Gong, Yuxiang Long, Guangliang Liu, Kai Wang, Mengshi Xia, Yanping Xu, Yuehui Yin
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
autophagy
cardiac remodeling
diastolic function
HFpEF
SGLT2 inhibitor
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.040093
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.040093

Similar Items